Cargando…
Androstenedione and Follicle-Stimulating Hormone Concentration Predict the Progression of Frailty Syndrome at One Year Follow-Up in Patients with Localized Breast Cancer Treated with Aromatase Inhibitors
Background: The standard treatment in postmenopausal women with estrogen- and progesterone-positive localized breast cancer consists of aromatase inhibitors (AROi). The ability of AROi to promote or worsen frailty syndrome over time and the relationship with changes in gonadal hormones concentration...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9312841/ https://www.ncbi.nlm.nih.gov/pubmed/35884939 http://dx.doi.org/10.3390/biomedicines10071634 |
_version_ | 1784753932086542336 |
---|---|
author | García-Sánchez, Javier Mafla-España, Mayra Alejandra Torregrosa, María Dolores Cauli, Omar |
author_facet | García-Sánchez, Javier Mafla-España, Mayra Alejandra Torregrosa, María Dolores Cauli, Omar |
author_sort | García-Sánchez, Javier |
collection | PubMed |
description | Background: The standard treatment in postmenopausal women with estrogen- and progesterone-positive localized breast cancer consists of aromatase inhibitors (AROi). The ability of AROi to promote or worsen frailty syndrome over time and the relationship with changes in gonadal hormones concentration in blood have not been investigated. Methods: A prospective study to evaluate the relationship between frailty syndrome and gonadal hormones concentrations in blood at baseline (prior to AROi treatment) and after 6 and 12 months under AROi treatment in post-menopausal women with breast cancer. Frailty syndrome was evaluated by the Fried’ criteria. We evaluated whether hormone concentration at baseline could predict frailty syndrome at follow-up. Results: Multinomial regression analysis showed that of the different hormones, those significantly (p < 0.05) associated to the worsening of frailty syndrome were high androstenedione levels and low follicle-stimulating hormone (FSH) levels in blood. Receiver operating characteristic curve analysis showed both androstenedione and FSH significantly (p < 0.05) discriminate patients who developed or presented worsening of frailty syndrome over time, with acceptable sensitivity (approximately 80% in both cases) but low specificity (40%). Conclusion: Hormonal concentrations before AROi treatment constitute possible biomarkers to predict the progression of frailty syndrome. |
format | Online Article Text |
id | pubmed-9312841 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93128412022-07-26 Androstenedione and Follicle-Stimulating Hormone Concentration Predict the Progression of Frailty Syndrome at One Year Follow-Up in Patients with Localized Breast Cancer Treated with Aromatase Inhibitors García-Sánchez, Javier Mafla-España, Mayra Alejandra Torregrosa, María Dolores Cauli, Omar Biomedicines Article Background: The standard treatment in postmenopausal women with estrogen- and progesterone-positive localized breast cancer consists of aromatase inhibitors (AROi). The ability of AROi to promote or worsen frailty syndrome over time and the relationship with changes in gonadal hormones concentration in blood have not been investigated. Methods: A prospective study to evaluate the relationship between frailty syndrome and gonadal hormones concentrations in blood at baseline (prior to AROi treatment) and after 6 and 12 months under AROi treatment in post-menopausal women with breast cancer. Frailty syndrome was evaluated by the Fried’ criteria. We evaluated whether hormone concentration at baseline could predict frailty syndrome at follow-up. Results: Multinomial regression analysis showed that of the different hormones, those significantly (p < 0.05) associated to the worsening of frailty syndrome were high androstenedione levels and low follicle-stimulating hormone (FSH) levels in blood. Receiver operating characteristic curve analysis showed both androstenedione and FSH significantly (p < 0.05) discriminate patients who developed or presented worsening of frailty syndrome over time, with acceptable sensitivity (approximately 80% in both cases) but low specificity (40%). Conclusion: Hormonal concentrations before AROi treatment constitute possible biomarkers to predict the progression of frailty syndrome. MDPI 2022-07-07 /pmc/articles/PMC9312841/ /pubmed/35884939 http://dx.doi.org/10.3390/biomedicines10071634 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article García-Sánchez, Javier Mafla-España, Mayra Alejandra Torregrosa, María Dolores Cauli, Omar Androstenedione and Follicle-Stimulating Hormone Concentration Predict the Progression of Frailty Syndrome at One Year Follow-Up in Patients with Localized Breast Cancer Treated with Aromatase Inhibitors |
title | Androstenedione and Follicle-Stimulating Hormone Concentration Predict the Progression of Frailty Syndrome at One Year Follow-Up in Patients with Localized Breast Cancer Treated with Aromatase Inhibitors |
title_full | Androstenedione and Follicle-Stimulating Hormone Concentration Predict the Progression of Frailty Syndrome at One Year Follow-Up in Patients with Localized Breast Cancer Treated with Aromatase Inhibitors |
title_fullStr | Androstenedione and Follicle-Stimulating Hormone Concentration Predict the Progression of Frailty Syndrome at One Year Follow-Up in Patients with Localized Breast Cancer Treated with Aromatase Inhibitors |
title_full_unstemmed | Androstenedione and Follicle-Stimulating Hormone Concentration Predict the Progression of Frailty Syndrome at One Year Follow-Up in Patients with Localized Breast Cancer Treated with Aromatase Inhibitors |
title_short | Androstenedione and Follicle-Stimulating Hormone Concentration Predict the Progression of Frailty Syndrome at One Year Follow-Up in Patients with Localized Breast Cancer Treated with Aromatase Inhibitors |
title_sort | androstenedione and follicle-stimulating hormone concentration predict the progression of frailty syndrome at one year follow-up in patients with localized breast cancer treated with aromatase inhibitors |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9312841/ https://www.ncbi.nlm.nih.gov/pubmed/35884939 http://dx.doi.org/10.3390/biomedicines10071634 |
work_keys_str_mv | AT garciasanchezjavier androstenedioneandfolliclestimulatinghormoneconcentrationpredicttheprogressionoffrailtysyndromeatoneyearfollowupinpatientswithlocalizedbreastcancertreatedwitharomataseinhibitors AT maflaespanamayraalejandra androstenedioneandfolliclestimulatinghormoneconcentrationpredicttheprogressionoffrailtysyndromeatoneyearfollowupinpatientswithlocalizedbreastcancertreatedwitharomataseinhibitors AT torregrosamariadolores androstenedioneandfolliclestimulatinghormoneconcentrationpredicttheprogressionoffrailtysyndromeatoneyearfollowupinpatientswithlocalizedbreastcancertreatedwitharomataseinhibitors AT cauliomar androstenedioneandfolliclestimulatinghormoneconcentrationpredicttheprogressionoffrailtysyndromeatoneyearfollowupinpatientswithlocalizedbreastcancertreatedwitharomataseinhibitors |